KRAS and non-small cell lung carcinoma: STK11/LKB1 (KL), TP53 (KP), and CDKN2A/B inactivation combined with low NKX2-1 expression (KC) represent the major co-mutation patterns in KRAS-mutated NSCLC, each associated with distinct TME characteristics and differential responses to treatment (131).